erythromycin has been researched along with verapamil in 62 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.61) | 18.7374 |
| 1990's | 6 (9.68) | 18.2507 |
| 2000's | 30 (48.39) | 29.6817 |
| 2010's | 23 (37.10) | 24.3611 |
| 2020's | 2 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Cvetkovic, M; Fromm, MF; Kim, RB; Leake, B; Wilkinson, GR | 1 |
| Hasegawa, T; Hui, CS; Kitaichi, K; Miyamoto, KI; Sakai, M; Takagi, K; Wang, L; Yokogawa, K | 1 |
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Fischer, H; Huwyler, J; Poli, S; Schwab, D; Tabatabaei, A | 1 |
| Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P | 1 |
| Du, LP; Li, MY; Tsai, KC; Xia, L; You, QD | 1 |
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Pratim Roy, P; Roy, K | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Balani, SK; Gan, LS; Li, P; Lu, C | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barreca, ML; Cannalire, R; Cecchetti, V; Couto, I; Felicetti, T; Machado, D; Manfroni, G; Massari, S; Sabatini, S; Santos Costa, S; Tabarrini, O; Viveiros, M | 1 |
| Abdel-Raziq, MS; Gabr, MT | 1 |
| Abutaleb, NS; Elsebaei, MM; Gowher, H; Mayhoub, AS; Michie, AR; Mohammad, H; Moustafa, MM; Norvil, AB; Samir, A; Samy, H; Seleem, MN | 1 |
| Guo, HF; Jin, J; Li, ZR; Liu, ZY; Xie, ZS; Xue, ST; Yi, H; Zhang, L | 1 |
| Bora, A; Deka, B; Devi, MV; Dihingia, A; Pahari, P; Sarma, S; Sen, T; Singh, AK; Suri, M | 1 |
| Hofsli, E; Nissen-Meyer, J | 2 |
| Kantola, T; Kivistö, KT; Neuvonen, PJ | 1 |
| Kanoh, S; Kondo, M; Miyazaki, S; Nagai, A; Shirakawa, H; Tamaoki, J | 1 |
| Fukuda, T; Hasegawa, R; Murakami, T; Nagai, J; Takano, M; Yumoto, R | 1 |
| Barnas, CR; Gorski, JC; Krecic-Shepard, ME; Schwartz, JB; Slimko, J; Wainer, IW | 1 |
| Iga, T; Kotaki, H; Matsuo, H; Sawada, Y; Takedomi, S; Yamamoto, K; Yamano, K | 1 |
| Barnas, CR; Jones, MP; Krecic-Shepard, ME; Schwartz, JB; Slimko, J | 1 |
| Chida, K; Ichiyama, A; Kanai, M; Nakamura, H; Oki, Y; Suda, T; Uchida, C; Xue, HH; Zhao, DM | 1 |
| Amaral, L; Farkas, S; Gunics, G; Molnár, J; Motohashi, N | 1 |
| Crespi, CL; Fox, L; Hu, M; Steimel, DT; Stocker, P | 1 |
| Murakami, T; Nagai, J; Nasu, R; Sanemasa, M; Takano, M; Yumoto, R | 1 |
| Azaz-Livshits, T; Ben-Yehuda, A; Goldschmidt, N; Muszkat, M; Nir-Paz, R | 1 |
| Li, J; Liu, F; Wang, C; Zhang, Q; Zhang, Y | 1 |
| Hankø, E; Hansen, TW; Tommarello, S; Watchko, JF | 1 |
| Hall, K; Meredith, S; Murray, KT; Narasimhulu, SS; Ray, WA; Stein, CM | 1 |
| Dorani, H; Eriksson, UG; Fritsch, H; Hoffmann, KJ; Karlsson, J; Olsson, L; Sarich, TC; Schützer, KM; Wall, U | 1 |
| Dakhel, Y; Jamali, F | 1 |
| Itoh, Z; Koga, H; Omura, S; Ozaki, K; Takanashi, H; Yogo, K | 1 |
| Arsenijević, S; Grujicić, D; Marinković, D; Milosević Djordjević, O | 1 |
| Boulenc, X; Hachad, H; Levy, RH; Ragueneau-Majlessi, I; Rauch, C | 1 |
| Hippalgaonkar, K; Majumdar, S; Srirangam, R | 1 |
| Avula, B; Hippalgaonkar, K; Khan, IA; Majumdar, S; Srirangam, R | 1 |
| Chen, Y; Fretland, AJ; Liu, L; Monshouwer, M | 1 |
| Kataoka, M; Masaoka, Y; Sakuma, S; Yamashita, S; Yokoyama, T | 1 |
| Biertz, J; Breithardt, G; Eckardt, L; Fink, M; Frommeyer, G; Koopmann, M; Milberg, P; Mönnig, G; Osada, N; Pott, C; Stypmann, J | 1 |
| Nikiteas, N; Perrea, D; Tsigris, C; Yiannakopoulou, E | 1 |
| Das, T; Foroutan, P; Gatenby, RA; Gillies, RJ; Kam, Y; Martinez, G; Minton, S; Ruiz, E; Tian, H | 1 |
| Engelen, A; Gerisch, M; Heinig, R; Loewen, S; Nagelschmitz, J | 1 |
3 review(s) available for erythromycin and verapamil
| Article | Year |
|---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacological modulation of oxidative stress response in minimally invasive surgery: systematic review.
Topics: Acetylcysteine; Animals; Antioxidants; Biomarkers; Erythromycin; Humans; Laparoscopy; Melatonin; Mesna; Oxidative Stress; Pentoxifylline; Pneumoperitoneum, Artificial; Rabbits; Rats; Verapamil; Zinc Compounds | 2012 |
3 trial(s) available for erythromycin and verapamil
| Article | Year |
|---|---|
Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations.
Topics: Adult; Anti-Bacterial Agents; Calcium Channel Blockers; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Erythromycin; Female; Humans; Hypolipidemic Agents; Male; Mixed Function Oxygenases; Reference Values; Simvastatin; Verapamil | 1998 |
Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biological Availability; Blood Pressure; Breath Tests; Calcium Channel Blockers; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Erythromycin; Female; Heart Rate; Humans; Injections, Intravenous; Liver; Male; Middle Aged; Mixed Function Oxygenases; Sex Factors; Verapamil | 2000 |
Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo.
Topics: Adult; Biological Availability; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Erythromycin; Gastric Mucosa; Gemfibrozil; Hepatocytes; Humans; In Vitro Techniques; Liver; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Naphthyridines; Verapamil; Young Adult | 2018 |
56 other study(ies) available for erythromycin and verapamil
| Article | Year |
|---|---|
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
Topics: Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Caco-2 Cells; Carrier Proteins; Genes, MDR; HeLa Cells; Histamine H1 Antagonists; Humans; LLC-PK1 Cells; Mice; Rats; Swine; Terfenadine; Tissue Distribution; Transfection; Vaccinia virus | 1999 |
Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Cell Membrane; Cell Survival; Cyclosporine; Drug Resistance, Neoplasm; Immunosuppressive Agents; Leukemia P388; Macrolides; Mice; Neoplasm Transplantation; Tumor Cells, Cultured; Verapamil; Vinblastine | 2000 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Drug Evaluation, Preclinical; Fluoresceins; Fluorescent Dyes; Humans; Indicators and Reagents; Mice; Models, Molecular; Rhodamines; Species Specificity; Swine | 2003 |
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties | 2004 |
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Models, Biological; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
Topics: Algorithms; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Factor Analysis, Statistical; Least-Squares Analysis; Linear Models; Models, Molecular; Neural Networks, Computer; Quantitative Structure-Activity Relationship; Reproducibility of Results | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Inhibitory Concentration 50; Microsomes, Liver; Time Factors | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
Topics: Anti-Bacterial Agents; Drug Design; Genistein; Mycobacterium avium; Quinolones | 2017 |
Structure-based design, synthesis, and evaluation of structurally rigid donepezil analogues as dual AChE and BACE-1 inhibitors.
Topics: Acetylcholinesterase; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Crystallography, X-Ray; Donepezil; Dose-Response Relationship, Drug; Drug Design; Humans; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2018 |
Lipophilic efficient phenylthiazoles with potent undecaprenyl pyrophosphatase inhibitory activity.
Topics: Animals; Anti-Bacterial Agents; Carbon-13 Magnetic Resonance Spectroscopy; Cell Line; Chromatography, Liquid; Enzyme Inhibitors; Lipids; Macrophages; Mass Spectrometry; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Proton Magnetic Resonance Spectroscopy; Pyrophosphatases; Structure-Activity Relationship; Thiazoles | 2019 |
Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties.
Topics: Animals; Benzofurans; Bone Morphogenetic Protein 2; Caco-2 Cells; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Mice; Mice, Inbred BALB C; Molecular Structure; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thiophenes; Zebrafish | 2020 |
Potentiating the intracellular killing of Staphylococcus aureus by dihydroquinazoline analogues as NorA efflux pump inhibitor.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cell Survival; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Molecular Structure; Multidrug Resistance-Associated Proteins; Quinazolines; Staphylococcus aureus; Structure-Activity Relationship; THP-1 Cells | 2022 |
Reversal of multidrug resistance by lipophilic drugs.
Topics: Animals; Cells, Cultured; Dactinomycin; Dose-Response Relationship, Drug; Drug Resistance; Drug Synergism; Erythromycin; Lipid Metabolism; Mice; Pentazocine; Tumor Necrosis Factor-alpha; Verapamil | 1990 |
Effect of erythromycin and tumour necrosis factor on the drug resistance of multidrug-resistant cells: reversal of drug resistance by erythromycin.
Topics: Animals; Antineoplastic Agents; Coloring Agents; Dactinomycin; Doxorubicin; Drug Interactions; Drug Resistance; Drug Synergism; Erythromycin; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Verapamil | 1989 |
Erythromycin inhibits ATP-induced intracellular calcium responses in bovine tracheal epithelial cells.
Topics: Adenosine Triphosphate; Animals; Anti-Bacterial Agents; Calcium; Cattle; Cells, Cultured; Erythromycin; Fluorescence; Fura-2; Image Processing, Computer-Assisted; Lanthanum; Trachea; Uridine Triphosphate; Verapamil | 1998 |
Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells.
Topics: Anti-Bacterial Agents; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Caco-2 Cells; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Erythromycin; GABA Modulators; Humans; Ketoconazole; Midazolam; Oxidoreductases, N-Demethylating; Rhodamine 123; Substrate Specificity; Vasodilator Agents; Verapamil | 1998 |
In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antitussive Agents; Area Under Curve; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Erythromycin; Female; Humans; Infusions, Intravenous; Linear Models; Male; Middle Aged; Mixed Function Oxygenases; Reference Values; Verapamil | 1999 |
Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: implication of concentrative uptake of inhibitors into liver.
Topics: Animals; Blood Proteins; Diltiazem; Drug Interactions; Erythromycin; Hypnotics and Sedatives; Liver; Male; Midazolam; Protein Binding; Rats; Rats, Sprague-Dawley; Verapamil | 2000 |
Effect of erythromycin on ATP-induced intracellular calcium response in A549 cells.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Adenosine Triphosphate; Anti-Bacterial Agents; Calcium; Calcium Channel Agonists; Calcium Channel Blockers; Erythromycin; Estrenes; Humans; Inositol 1,4,5-Trisphosphate; Intracellular Membranes; Lung; Nickel; Potassium Chloride; Protein Isoforms; Pyrrolidinones; Receptors, Purinergic P2; Receptors, Purinergic P2X2; Tumor Cells, Cultured; Uridine Triphosphate; Verapamil | 2000 |
Interaction between antibiotics and non-conventional antibiotics on bacteria.
Topics: Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Antipruritics; Bacteria; Calcium Channel Blockers; Clomipramine; Drug Combinations; Drug Interactions; Drug Resistance, Microbial; Erythromycin; Escherichia coli; Gentamicins; Humans; Methylene Blue; Promethazine; Pseudomonas aeruginosa; Selective Serotonin Reuptake Inhibitors; Staphylococcus epidermidis; Tetracycline; Verapamil | 2000 |
Analysis of drug transport and metabolism in cell monolayer systems that have been modified by cytochrome P4503A4 cDNA-expression.
Topics: Animals; Atenolol; Biological Transport; Cell Line; Cell Membrane Permeability; Cimetidine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; DNA, Complementary; Erythromycin; Glucose; Humans; Mammals; Mannitol; Mixed Function Oxygenases; Pharmaceutical Preparations; Phenylalanine; Propranolol; Recombinant Proteins; Testosterone; Tumor Cells, Cultured; Verapamil | 2000 |
Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biliary Tract; Blotting, Western; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Drug Interactions; Erythromycin; Intestinal Absorption; Intestines; Liver; Male; Midazolam; Oxidoreductases, N-Demethylating; Rats; Rats, Wistar; Rhodamine 123; Substrate Specificity; Verapamil | 2001 |
Compound cardiac toxicity of oral erythromycin and verapamil.
Topics: Aged; Anti-Bacterial Agents; Blood Cell Count; Calcium Channel Blockers; Electrocardiography; Erythromycin; Female; Heart Block; Humans; Long QT Syndrome; Verapamil | 2001 |
Establishment of multidrug-resistance cell line C(6)/adr and reversal of drug-resistance.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erythromycin; Gene Expression Regulation, Neoplastic; Humans; Tumor Cells, Cultured; Verapamil | 2002 |
Administration of drugs known to inhibit P-glycoprotein increases brain bilirubin and alters the regional distribution of bilirubin in rat brain.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bilirubin; Blood-Brain Barrier; Brain; Calcium Channel Blockers; Ceftriaxone; Enzyme Inhibitors; Erythromycin; Female; Humans; Male; Propranolol; Rats; Rats, Sprague-Dawley; Rifampin; Verapamil | 2003 |
Oral erythromycin and the risk of sudden death from cardiac causes.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Calcium Channel Blockers; Confounding Factors, Epidemiologic; Cytochrome P-450 CYP3A; Death, Sudden, Cardiac; Diltiazem; Drug Interactions; Erythromycin; Female; Humans; Male; Middle Aged; Multivariate Analysis; Nitroimidazoles; Oxidoreductases, N-Demethylating; Risk; Troleandomycin; Verapamil | 2004 |
Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion.
Topics: Adult; Animals; Anti-Bacterial Agents; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azetidines; Benzylamines; Bile; Biological Transport, Active; Caco-2 Cells; Calcium Channel Blockers; Cell Line; Dogs; Dose-Response Relationship, Drug; Drug Interactions; Erythromycin; Female; Humans; In Vitro Techniques; Male; Partial Thromboplastin Time; Quinidine; Rats; Rats, Sprague-Dawley; Verapamil | 2006 |
Erythromycin potentiates PR interval prolonging effect of verapamil in the rat: a pharmacodynamic drug interaction.
Topics: Animals; Anti-Bacterial Agents; Blood Proteins; Calcium Channel Blockers; Drug Synergism; Electrocardiography; Erythromycin; Heart Conduction System; In Vitro Techniques; Male; Protein Binding; Rats; Rats, Sprague-Dawley; Verapamil | 2006 |
In vitro pharmacological characterization of mitemcinal (GM-611), the first acid-resistant non-peptide motilin receptor agonist, in smooth muscle of rabbit small intestine.
Topics: Acetylcholine; Animals; Atropine; Binding, Competitive; Calcium Chloride; Diltiazem; Dose-Response Relationship, Drug; Erythromycin; Hexamethonium; Hydrogen-Ion Concentration; In Vitro Techniques; Indoles; Intestine, Small; Male; Molecular Structure; Muscle Contraction; Muscle, Smooth; Naloxone; Rabbits; Receptors, Gastrointestinal Hormone; Receptors, Neuropeptide; Tetrodotoxin; Tropisetron; Verapamil | 2007 |
The effect of combined therapy with ritodrine, erythromycin and verapamil on the frequency of micronuclei in peripheral blood lymphocytes of pregnant women.
Topics: Adult; Cerclage, Cervical; Drug Therapy, Combination; Erythromycin; Female; Humans; Lymphocytes; Micronuclei, Chromosome-Defective; Micronucleus Tests; Pregnancy; Ritodrine; Tocolytic Agents; Uterine Cervical Incompetence; Verapamil | 2007 |
Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Databases, Factual; Drug Interactions; Enzyme Inhibitors; Erythromycin; Fluconazole; Ketoconazole; Midazolam; Substrate Specificity; Verapamil | 2007 |
Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators.
Topics: Administration, Topical; Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Drug Interactions; Erythromycin; Fluorescein; Fluorescent Dyes; Half-Life; Male; Metabolic Clearance Rate; Ophthalmic Solutions; Prednisolone; Quinidine; Rabbits; Tissue Distribution; Verapamil; Vitreous Body | 2009 |
Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics.
Topics: Administration, Topical; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Interactions; Erythromycin; Injections, Intravenous; Male; Mass Spectrometry; Microdialysis; Ophthalmic Solutions; Prednisolone; Quinidine; Rabbits; Substrate Specificity; Time Factors; Tissue Distribution; Verapamil; Vitreous Body | 2010 |
Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions.
Topics: Cryopreservation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Diltiazem; Drug Interactions; Enzyme Activation; Enzyme Inhibitors; Erythromycin; Hepatocytes; Humans; Microsomes, Liver; Pharmacokinetics; Risk Assessment; Time Factors; Troleandomycin; Verapamil | 2011 |
Estimation of P-glycoprotein-mediated efflux in the oral absorption of P-gp substrate drugs from simultaneous analysis of drug dissolution and permeation.
Topics: Algorithms; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Drug Interactions; Erythromycin; Gene Expression; Glycerol; Humans; Intestinal Absorption; Loperamide; Models, Biological; Pharmaceutical Preparations; Propanolamines; Puromycin; Quinidine; Saquinavir; Solubility; Surface-Active Agents; Terfenadine; Verapamil; Vinblastine | 2011 |
Blockade of I(Ca) suppresses early afterdepolarizations and reduces transmural dispersion of repolarization in a whole heart model of chronic heart failure.
Topics: Action Potentials; Animals; Calcium; Calcium Channel Blockers; Erythromycin; Female; Heart; Heart Failure; Models, Biological; Myocytes, Cardiac; Potassium Channel Blockers; Rabbits; Tachycardia, Ventricular; Verapamil | 2012 |
Sweat but no gain: inhibiting proliferation of multidrug resistant cancer cells with "ersatzdroges".
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Proliferation; Cell Survival; Clarithromycin; Cyclosporine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erythromycin; Female; Gene Expression; Humans; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice, Nude; Molecular Targeted Therapy; Tumor Burden; Verapamil; Xenograft Model Antitumor Assays | 2015 |